Dr. Eric Schordan, Head of the Molecular Diagnostic Department at Firalis and TcLand Expression, led a project that aimed to develop personalized treatment strategies for rheumatoid arthritis patients using miRNA profiling. In this webinar, Dr. Schordan will discuss the details of that study, as well as his team's plans to validate the panel in a multicentric prospective clinical study of 600 patients.
VIDEO
Millions of patients with rheumatoid arthritis are treated with TNF-α inhibiting agents, but the response rate to these therapies is low (30 percent to 40 percent) and no tool exists to predict treatment response.
Using the HTG EdgeSeq platform, Dr. Schordan and colleagues first identified sets of miRNAs that discriminate responders from non-responders to anti TNF-α therapy and then developed a panel called RABIOPRED that includes more than 2,100 mRNAs identified as predictors of anti TNF-α therapy.
In a study that enrolled 67 RA patients, Dr. Schordan and his team determined that miRNA profiling using the HTG EdgeSeq platform served as a useful tool for biomarker discovery and enabled them to build predictive models for response to anti-TNF-α drugs.
Click here (HTG-Firalis July 2016) to download the presentation
If you want to download the slide kit presented during the webinar, click here.
FIRALIS SA
35 Rue du Fort
68330 Huningue
France
+33 389 910 111
contact@firalis.com
www.firalis.com
http://www.rabiopred-project-h2020.eu/